Citations

Clear

24 citation(s) found for "Carroll, Andrew J".

A complete human pancreatic cancer genome
Wagner, Justin , Keskus, Ayse G. , Oshima, Keisuke K. , Ranallo-Benavidez, T. Rhyker , McDaniel, Jennifer , Šikić, Mile , Lin, Dehui , Paulin, Luis F. , Sedlazeck, Fritz J. , Munding, Elizabeth M., Sanborn, JZ, Carroll, Andrew, Hassaine, Rayan, Cameron, Daniel, Catreux, Severine , Lee, Yeonghun , Murray, Lisa , Truong, Sean , Zimin, Aleksey V. , Cross, Erin , McGowan, Matthew , Vernich, Michael, Liss, Andrew S., Kocher, Jean-Pierre, Stephens, Zachary, Ahmad, Tanveer, Bryant, Asher , Dwarshuis, Nathan , Thibaud-Nissen, Francoise, Antipov, Dmitry, Koren, Sergey, Phillippy, Adam, Jain, Miten , Wenger, Aaron M. , Eacker, Stephen, Sahraeian, Sayed Mohammad Ebrahim, Boutros, Paul C., Patel, Yash, McConnell, Joseph , Borchers, Matthew , Gerton, Jennifer L. , Kostos, Paxton, Benjamin, Hila, Mootor, Mohammed Faizal Eeman , Xu, Yuan , Asri, Mobin , Miga, Karen H. , Park, Jimin , Paten, Benedict , Choi, Jae Young , Nguyen, L. , Robinson, Dan R. , Vo, Josh N. , Murtaza, Ghulam , Mason, Christopher E. , Cheng, Haoyu, Xiao, Chunlin , English, Adam C , Sedlazeck, Fritz J , Sanborn, J Zachary , Carroll, Andrew , Chang, Pi-Chuan , Cook, Daniel E , Shafin, Kishwar , de Ligt, Joep , Cameron, Daniel , Catreux, Severine , Lee, Yeonghun , Murray, Lisa , Truong, Sean , Brueffer, Christian , Cross, Erin , McGowan, Matthew , Vernich, Michael , Liss, Andrew S , Kocher, Jean-Pierre A , Stephens, Zachary , He, Hua-Jun , He, Zhiyong , Olson, Nathan D , Narzisi, Giuseppe , Jain, Miten , Wenger, Aaron M , Boutros, Paul C , Patel, Yash , Yamaguchi, Takafumi N , McConnell, Joseph , Gerton, Jennifer L , Guarracino, Andrea , Jehangir, Maryam , Mootor, Mohammed Faizal Eeman , Xu, Yuan , Miga, Karen H , Park, Jimin , Paten, Benedict , Luo, Ruibang , Zheng, Zhenxian , Choi, Jae Young , Nguyen, Linh , Vats, Pankaj , Gao, Shenghan , Murtaza, Ghulam , Mason, Christopher E , Barthel, Floris P , Xiao, Chunlin , Logsdon, Glennis A , Kolmogorov, Mikhail , Zook, Justin M , Keskus, Ayse , Ranallo-Benavidez, T Rhyker , Paulin, Luis F. , Sanborn, John Z., Ahmad, Tanveer, Thibaud‐Nissen, Françoise , Antipov, Dmitry , Koren, Sergey , Phillippy, Adam M. , Musunuri, Rajeeva , Eacker, Stephen M. , Yamaguchi, Takafumi N. , Jehangir, Maryam , Benjamin, Hila

Mayo Clinic

No container title available | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.01.722316 | PMID 42146349 Get It

Summary Cancer genome sequencing is essential for understanding tumor evolution and advancing precision medicine. 1 However, reference gaps and germline variants obscure detection of small and large somatic variants and methylation in repetitive regions. 1–3 It is common for tumor cells to gain or lose chromosome arms due to somatic structural changes that occur inside highly repetitive satellite DNA sequences in the centromeres. 4 To identify the full spectrum of somatic variants, including complex rearrangements, we construct and curate near-complete, haplotype-resolved assemblies of the most recent common ancestor of an early-passage broadly-consented hypodiploid pancreatic cancer cell line and matched normal tissues. The tumor assembly completely recapitulates all 35 tumor chromosomes observed with karyotyping, with multiple translocation-induced hybrid chromosomes. The hybrid chromosomes contain putative functional dicentric and fused centromeres, nested foldback inversions causing 14 breakpoints with a haplotype switch in a single event, and centromeric satellite tandem duplications up to 136 kbp. Direct comparison of tumor and normal assembly haplotypes uncovers >7,000 variants altering >1 Mbp of sequence in repetitive regions that have been hidden by reference gaps and germline variants. 44 % of somatic small variants change representation because they alter germline variants on GRCh38, impacting mutational signatures and kataegis/omikli clusters. Most somatic LINE insertions originate from two hypomethylated non-reference germline LINE insertions, highlighting their impact on insertion mutation burden. These assemblies demonstrate that centromeric, acrocentric, and telomeric regions conventionally excluded from analysis harbor extensive somatic and epigenetic changes. Resolving complete tumor genomes enables a deeper understanding of cancer structural plasticity and the endpoints of breakage-fusion-bridge cycles. These assembled, curated paired normal-tumor benchmarks will serve as a critical foundation for developing future algorithms to characterize the most intractable regions of cancer genomes.
A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)
Uy, Geoffrey, Yin, Jun, Dinner, Shira, Jacoby, Meagan, Deangelo, Daniel, Liesveld, Jane, Kolitz, Jonathan, Asch, Adam, Odenike, Olatoyosi, Kour, Oudom, Skogen, Korrie, Byrd, Ken, Little, Richard, Gore, Steven, Carroll, Andrew, Mrózek, Krzysztof, Byrd, John, Eisfeld, Ann-Kathrin, Jaslowski, Anthony, Erba, Harry, Litzow, Mark, Stock, Wendy, Stone, Richard, Uy, Geoffrey, Yin, Jun, Dinner, Shira, Jacoby, Meagan, Deangelo, Daniel, Liesveld, Jane, Kolitz, Jonathan, Asch, Adam, Odenike, Olatoyosi, Kour, Oudom, Skogen, Korrie, Byrd, Ken, Little, Richard, Gore, Steven, Carroll, Andrew, Mrózek, Krzysztof, Byrd, John, Eisfeld, Ann-Kathrin, Jaslowski, Anthony, Erba, Harry, Litzow, Mark, Stock, Wendy, Stone, Richard

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3415-3415

10.1182/blood-2025-3415 Get It

Abstract Background. Uproleselan (GMI-1271) is an antagonist of E-selectin, an adhesion molecule expressed on endothelial cells in the vascular niche of the bone marrow. Engagement of E-selectin by acute myeloid leukemia (AML) blasts, which express E-selectin ligand, activates cell survival pathways and promotes resistance to chemotherapy. In multiple preclinical AML tumor models, blockade of E-selectin with uproleselan enhanced the efficacy of chemotherapy. Methods. We conducted a phase (P) 2/3 study in which subjects age ≥ 60 years with untreated, FLT3 unmutated AML were randomized to receive conventional chemotherapy with or without uproleselan. Induction chemotherapy consisted of 7+3 (cytarabine + daunorubicin) +/- uproleselan with a second induction cycle with 5+2 +/- uproleselan administered for residual AML. Uproleselan 800 mg IV was administered as a single dose 24 hours before the first dose of chemotherapy and then every 12 hours until 48 hours after the completion of chemotherapy. Post-remission therapy consisted of up to 3 cycles intermediate-dose cytarabine 2 gm/m2 IV d1-5 +/- uproleselan. Allogeneic transplant was performed at the discretion of the treating physician. The primary endpoint was event-free survival (EFS) for P2 and overall survival (OS) for P3. Results. The study enrolled 267 patients between March 2019 and November 2021, with a median age of 66.9 years (IQR 63.8-69.9). 32% were classified as 2017 ELN intermediate risk, 41% as adverse risk, with 62 (29%) having complex karyotype / mutated TP53. The P2 analysis was to be performed when at least 191 events were observed. However, as the required events had not been observed > 5 years after study initiation and 3 years after completion of P2 enrollment, an independent statistician was consulted, and the analysis plan was amended to conduct the P2 EFS analysis in November 2024. With a median follow-up of 53.1 months, the EFS was not significantly different between the two arms (HR 0.90, 95% CI 0.70-1.23, P=0.58). As the study did not meet its P2 EFS endpoint, enrollment in the P3 was not initiated. There was no significant difference in OS between the 2 arms (HR 0.99, p=0.94) with a median OS in the uproleselan arm of 23.6 months (95% CI 15.1-35.4 mo) vs 19.8 months (14.6-36.3) for the control arm. The overall rate of CR/CRi after induction was 65% (CR: 60%) in the uproleselan arm versus 63% (CR: 55%) in the control. MRD results by either local or central assessment in patients achieving a CR/CRi were available for 129 patients with the MRDneg rate of 81 % (95% CI 69.5-89.9%) in the uproleselan arm vs 67% (54.3-78.4%) in the control arm (p=0.053), The 30-day mortality was 5.3% for uproleselan vs 8.1% in the control. Forty-eight (36%) patients in the uproleselan arm and 55 (40%) in the control arm underwent alloHCT, including 37 (27%) and 29 (22%) in CR1, respectively (p = 0.34). In patients undergoing alloHCT in CR1, those randomized to uproleselan and allografted in CR1 had an HR 0.71 (95% CI 0.34-1.47; P=0.35) compared to the control arm. Expression of E-selectin ligand on AML blasts was performed by flow cytometry, with subjects having an E-selectin ligand expression above the median having a trend towards worse median OS 16.2 (95% CI 11.4-24.3) vs 32.2 (15.9-57.8) months, but was not affected by treatment arm. In both univariate and multivariate analyses, WBC at baseline, ELN genetic risk group, and TP53/complex karyotype were found to be associated with EFS. A subgroup analysis identified an improvement in EFS favoring uproleselan in patients with mutated ASXL1 (HR 0.25, 95% CI 0.08-0.78, p<0.017). Conclusions. Although the addition of uproleselan to intensive chemotherapy was associated with a higher rate of MRDneg CR/CRi in older adults with AML, uproleselan failed to improve EFS or OS and did not overcome the adverse outcomes associated with higher E-selectin expression on AML blasts. The median OS of 20-24 months with an overall 3-year OS of almost 40% for patients treated on this study exceeds previous CALGB / US Cooperative Group studies (median OS ~12 months, 3-year OS ~20%) and continues to support a role for intensive chemotherapy in the management of older adults with AML. Furthermore, this study suggests a potential benefit for uproleselan in patients harboring ASXL1 mutations, which may warrant further investigation. ClinicalTrials.gov Identifier: NCT03701308
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia
Chang, Ti‐Cheng , Chen, Wenan , Cheng, Zhongshan , Hedges, Dale J., Elsayed, Abdelrahman , Pounds, Stanley , Shago, Mary , Rabin, Karen R. , Raetz, Elizabeth A. , Cheng, Cheng , Angiolillo, Anne , Baviskar, Pradyuamna , Borowitz, Michael J., Carroll, Andrew J. , Carroll, William L. , Heerema, Nyla A. , Larsen, Eric , Mattano, Leonard A. , Maloney, Kelly W. , Ramirez, Nilsa C. , Salzer, Wanda L. , Wu, Gang , Loh, Mignon L. , Wu, Gang , Rabin, Karen R , Raetz, Elizabeth A , Devidas, Meenakshi , Baviskar, Pradyuamna , Burke, Michael J , Carroll, Andrew J , Harvey, Richard , Iacobucci, Ilaria , Wang, Jeremy R , Jeha, Sima , Mattano, Leonard A , Maloney, Kelly W , Pui, Ching-Hon , Ramirez, Nilsa C , Willman, Cheryl , Wood, Brent L , Hunger, Stephen P , Mullighan, Charles G , Loh, Mignon L , Pounds, Stanley B , Wu, Gang , Qu, Chunxu , Devidas, Meenakshi , Chen, I‐Ming , Harvey, Richard C. , Iacobucci, Ilaria , Wang, Jeremy , Willman, Cheryl L. , Winick, Naomi Joan , Wood, Brent L. , Hunger, Stephen P. , Mullighan, Charles G.

Mayo Clinic

Journal of Clinical Oncology | August 9, 2024 | Volume: 42 | Issue: 29 | Pages: 3491-3503

10.1200/jco.23.02238 | PMID 39121442 Get It

PURPOSE Although cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 90%, ALL remains a leading cause of cancer death in children. Half of relapses arise in children initially classified with standard-risk (SR) disease. MATERIALS AND METHODS To identify genomic determinants of relapse in children with SR ALL, we performed genome and transcriptome sequencing of diagnostic and remission samples of children with SR (n = 1,381) or high-risk B-ALL with favorable cytogenetic features (n = 115) enrolled on Children's Oncology Group trials. We used a case-control study design analyzing 439 patients who relapsed and 1,057 who remained in complete remission for at least 5 years. RESULTS Genomic subtype was associated with relapse, which occurred in approximately 50% of cases of PAX5 -altered ALL (odds ratio [OR], 3.31 [95% CI, 2.17 to 5.03]; P = 3.18 × 10 –8 ). Within high-hyperdiploid ALL, gain of chromosome 10 with disomy of chromosome 7 was associated with favorable outcome (OR, 0.27 [95% CI, 0.17 to 0.42]; P = 8.02 × 10 –10 ; St Jude Children's Research Hospital validation cohort: OR, 0.22 [95% CI, 0.05 to 0.80]; P = .009), and disomy of chromosomes 10 and 17 with gain of chromosome 6 was associated with relapse (OR, 7.16 [95% CI, 2.63 to 21.51]; P = 2.19 × 10 –5 ; validation cohort: OR, 21.32 [95% CI, 3.62 to 119.30]; P = .0004). Genomic alterations were associated with relapse in a subtype-dependent manner, including alterations of INO80 in ETV6::RUNX1 ALL, IKZF1 , and CREBBP in high-hyperdiploid ALL and FHIT in BCR::ABL1 -like ALL. Genomic alterations were also associated with the presence of minimal residual disease, including NRAS and CREBBP in high-hyperdiploid ALL. CONCLUSION Genetic subtype, patterns of aneuploidy, and secondary genomic alterations determine risk of relapse in childhood ALL. Comprehensive genomic analysis is required for optimal risk stratification.
Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131
Salzer, Wanda L. , Chen, Zhiguo , Borowitz, Michael J., Carroll, Andrew J. , Chen, I-Ming L., Heerema, Nyla A. , Reshmi, Shalini C. , Carroll, William L. , Raetz, Elizabeth A. , Burke, Michael J , Devidas, Meenakshi , Gastier‐Foster, Julie M. , Harvey, Richard C. , Mullighan, Charles G. , Rabin, Karen R. , Willman, Cheryl L. , Wood, Brent L. , Winick, Naomi Joan , Loh, Mignon L. , Hunger, Stephen P.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 961-961

10.1182/blood-2023-190495 Get It

Background: Approximately 2-3% of B-ALL patients have Philadelphia chromosome like (Ph-like) B-ALL with an ABL-class fusion ( ABL1, ABL2, PDGFRB, or CSF1R fusions), but lacking BCR::ABL1. These patients are predicted to be sensitive to ABL-class tyrosine kinase inhibitors, such as imatinib or dasatinib. Ph-like B-ALL is associated with male sex, older age, higher initial white blood cell (WBC) count, elevated end of induction (EOI) minimal residual disease (MRD), and poor outcome. The AALL1131 Dasatinib arm was designed to evaluate response to therapy following induction of patients with ABL-class fusion B-ALL, when given dasatinib continuously on a modified Berlin-Frankfurt-Münster (MBFM) backbone. Methods: Between February 2012 and March 2019, AALL1131 enrolled patients 1-30 years with newly diagnosed high risk (HR) B-ALL. AALL1131 was amended in August 2016, to include the Dasatinib arm for patients with ABL-class fusions involving ABL1, ABL2, PDGFRB, and CSF1R. Patients with Down Syndrome were not eligible for the Dasatinib arm. ABL-class fusion B-ALL patients with a predicted TKI-sensitive mutation were screened by low density array (LDA) PCR and confirmed by additional molecular testing. Following 4-drug induction, patients with HR B-ALL and ABL-class fusions received MBFM with dasatinib (60 mg/m 2, maximum 140 mg) daily from start of consolidation through end of maintenance. Dasatinib was held only for toxicity. Results: Twenty-two evaluable patients with HR B-ALL were non-randomly assigned to the Dasatinib arm. ABL-class 3' partners included ABL1 (n=4), ABL2 (n=4), PDGFRB (n=12), and CSF1R (n=2). Compared to all patients on AALL1131, patients treated on the Dasatinib arm were older (median age at diagnosis 14 versus 10 years, p=0.008), more often male (77% versus 56%, p=0.046), and had a trend towards an increased initial WBC (median WBC at diagnosis 44,000/µL versus 19,000/µL, p=0.086). Patients with ABL-class fusions had EOI MRD > 0.01% in 20 of 22 patients and available end of consolidation MRD >0.01% in 6 of 10 patients. Only 5 of 22 (22.7%) patients completed prescribed protocol therapy. Reasons for therapy discontinuation included induction failure (n=2), relapse (n=1), alternate therapy (n=1), determined to be in the patient's best interest (n=10), death (n=1), unknown (n=2). Compared to all patients on AALL1131, four-year disease-free survival was 52.5+18.1% versus 86.8+0.7% (p<0.0001) and overall survival 79.4+13.6% versus 89.2+0.4% (p<0.0001). Dasatinib was well tolerated with no unexpected treatment related toxicities. Conclusion: Patients with ABL-class fusions were more likely male, EOI MRD+, and had poorer outcomes. Seventy-seven percent of patients enrolled on the Dasatinib arm did not complete prescribed therapy. While dasatinib was well tolerated, treatment failures occurred early, indicating alternate strategies are needed.
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group
Rabin, Karen R. , Chen, Zhiguo , Ji, Lingyun , Kairalla, John A. , Hitzler, Johann , Carroll, Andrew J. , Heerema, Nyla A. , Borowitz, Michael J., Reshmi, Shalini C. , Bhojwani, Deepa , Maloney, Kelly W. , Mattano, Leonard A. , Larsen, Eric , Salzer, Wanda L. , Carroll, William L. , Raetz, Elizabeth A. , Loh, Mignon L. , Angiolillo, Anne , Ji, Lingyun , Hitzler, Johann K , Yang, Jun J.J. , Carroll, Andrew J , Wood, Brent L , Roberts, Kathryn G , Mullighan, Charles G , Harvey, Richard , Willman, Cheryl , Gastier‐Foster, Julie M. , Rheingold, Susan R , Maloney, Kelly W , Mattano, Leonard A , Schore, Reuven J , Burke, Michael J , Winick, Naomi Joan , Raetz, Elizabeth A , Loh, Mignon L , Hunger, Stephen P , Rabin, Karen R , Devidas, Meenakshi , Wood, Brent L. , Roberts, Kathryn G. , Mullighan, Charles G. , Harvey, Richard C. , Chen, I‐Ming , Willman, Cheryl L. , Hunger, Stephen P.

Mayo Clinic

Journal of Clinical Oncology | October 27, 2023 | Volume: 42 | Issue: 2 | Pages: 218-227

10.1200/jco.23.00389 | PMID 37890117 Get It

PURPOSE Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on Children's Oncology Group trials between 2003 and 2019. METHODS We analyzed data for DS (n = 743) and non-DS (n = 20,067) patients age 1-30 years on four B-ALL standard-risk (SR) and high-risk trials. RESULTS Patients with DS exhibited more frequent minimal residual disease (MRD) ≥0.01% at end induction (30.8% v 21.5%; P < .001). This difference persisted at end consolidation only in National Cancer Institute (NCI) high-risk patients (34.0% v 11.7%; P < .0001). Five-year event-free survival (EFS) and overall survival (OS) were significantly poorer for DS versus non-DS patients overall (EFS, 79.2% ± 1.6% v 87.5% ± 0.3%; P < .0001; OS, 86.8% ± 1.4% v 93.6% ± 0.2%; P < .0001), and within NCI SR and high-risk subgroups. Multivariable Cox regression analysis of the DS cohort for risk factors associated with inferior EFS identified age >10 years, white blood count >50 × 103/μL, and end-induction MRD ≥0.01%, but not cytogenetics or CRLF2 overexpression. Patients with DS demonstrated higher 5-year cumulative incidence of relapse (11.5% ± 1.2% v 9.1% ± 0.2%; P = .0008), death in remission (4.9% ± 0.8% v 1.7% ± 0.1%; P < .0001), and induction death (3.4% v 0.8%; P < .0001). Mucositis, infections, and hyperglycemia were significantly more frequent in all patients with DS, while seizures were more frequent in patients with DS on high-risk trials (4.1% v 1.8%; P = .005). CONCLUSION Patients with DS-ALL exhibit an increased rate of relapse and particularly of treatment-related mortality. Novel, less-toxic therapeutic strategies are needed to improve outcomes.
A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1
Kairalla, John A. , Hibbitts, Emily , Carroll, Andrew J. , Heerema, Nyla A. , Kubaney, Holly R. , August, Amanda, Wechsler, Daniel S. , Miles, Rodney R., Kihei, Cynthia D., Gore, Lia , Raetz, Elizabeth A. , Brown, Patrick A. , Guest, Erin M. , Devidas, Meenakshi , Pauly, Melinda , Reid, Joel M. , Hunger, Stephen P. , Loh, Mignon L.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3256-3257

10.1182/blood-2022-167765 Get It

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Walker, Alison R. , Marcucci, Guido , Yin, Jun , Blum, William , Kohlschmidt, Jessica, Mrózek, Krzysztof , Carroll, Andrew J. , Eisfeld, Ann-Kathrin, Kolitz, Jonathan E. , Thakuri, Mohan C., Sutamtewagul, Grerk , Vij, Ravi , Byrd, John C. , Bloomfield, Clara D. , Stone, Richard M. , Byrd, John C. , Jacobson, Sawyer , Sutamtewagul, Grerk , Larson, Richard A , Stock, Wendy , Eisfeld, Ann‐Kathrin , Wang, Eunice S. , Stuart, Robert K. , Larson, Richard A. , Byrd, John C

Mayo Clinic

Blood Advances | July 12, 2021 | Volume: 5 | Issue: 13 | Pages: 2775-2787

10.1182/bloodadvances.2021004233 | PMID 34251414 Get It

Abstract Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. In this phase 3 trial, untreated older AML patients were randomized to cytarabine (100 mg/m2 per day on days 4-10) and daunorubicin (60 mg/m2 per day on days 4-6) followed by cytarabine consolidation (2000 mg/m2 per day on days 4-8) with (arm A) or without (arm B) G3139 (7 mg/m2 per day on days 1-10 [induction] or days 1-8 [consolidation]). A total of 506 patients were enrolled. No differences in toxicity were observed between arms. Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P = .13), with no differences in disease-free (DFS; P = .26) or event-free survival (P = .80). Subgroup analyses showed patients age &lt;70 years in arm A had improved OS by 1 month vs those in arm B (P = .04), and patients with secondary AML in arm A had better DFS vs those in arm B (P = .04). We conclude that addition of G3139 to chemotherapy failed to improve outcomes of older AML patients. However, more effective means of inhibiting BCL2 are showing promising results in combination with chemotherapy in AML. This trial was registered at www.clinicaltrials.gov as #NCT00085124.
Two Distinct Subsets of dic(9;12)(p12;p11.2) among Children with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL): PAX5-ETV6 and ETV6-RUNX1 Rearrangements: A Report from the Children’s Oncology Group.
Carroll, Andrew J. , Ell, Denise, Meloni‐Ehrig, Aurelia, Opheim, Kent E., Patil, Shivanand R., Pettenati, Mark J., Rao, Kathleen, Wu, Shiqi , Heerema, Nyla A. , Gastier‐Foster, Julie M. , Harvey, Richard C. , Chen, I‐Ming , Ketterling, Rhett P.

Mayo Clinic

Blood | April 18, 2020 | Volume: 110 | Issue: 11 | Pages: 1439-1439

10.1182/blood.v110.11.1439.1439 Get It

Abstract The dic(9;12)(p12;p11.2) has been described as a rare cytogenetic abnormality in pediatric precursor B-cell ALL. Initial studies suggested that the rearrangement is associated with a favorable outcome, and recent studies demonstrated the presence of a PAX5-ETV6 fusion gene was associated with this cytogenetic abnormality. Twenty cases with a cytogenetic dic(9;12) were identified in the Children’s Oncology Group (COG) cytogenetics databases. FISH analysis with the ETV6-RUNX1 (TEL-AML1) probes was done on 12 of these samples. Five cases were positive for fusion, indicating a cryptic t(12;21)(p13;q22), and also had loss of the ETV6 probe from the chromosome 12 not involved in the t(12;21). Seven cases were negative for fusion and had loss of an ETV6 signal, although one of the latter had a diminished ETV6 signal identified. To determine whether both PAX5-ETV6 and ETV6-RUNX1 rearrangements occurred in some patients, a diagnostic sample from each patient was analyzed by RT-PCR for the PAX5-ETV6 and ETV6-RUNX1 fusion genes. Primers from exon 3 of PAX5 and exon 3 of ETV6 were used for the PAX5-ETV6 analysis and from exon 5 of ETV6 and exon 4 of RUNX1 for the ETV6-RUNX1 analysis. Of the 20 cases, only 8 were RT-PCR positive for the PAX5-ETV6 fusion with the above primers; however, an additional 2 were RT-PCR positive with alternate primers, and all 10 of these were negative for the ETV6-RUNX1 fusion by RT-PCR. Of the remaining 10 patients, 9 were RT-PCR positive for the ETV6-RUNX1 fusion, including all of the ETV6-RUNX1 cases positive by FISH. The gene rearrangement associated with the dic(9;12) in these cases is not known. One patient was negative for both fusions by RT-PCR, negative by FISH for ETV6-RUNX1 rearrangement, yet had loss of an ETV6 signal. No cytogenetic differences could be seen between the 2 groups, either in the appearance of the dic(9;12) or in the other abnormalities identified. These results demonstrate the presence of two mutually exclusive dic(9;12) rearrangements in pediatric ALL; one associated with ETV6-RUNX1 rearrangement and one resulting in PAX5-ETV6 fusion. Both PAX5-ETV6 and ETV6-RUNX1 rearrangements are associated with a favorable prognosis. However, molecular analysis of the dic(9;12) patients must be performed to determine whether the dicentric chromosome results in PAX5-ETV6 fusion or whether the case has ETV6-RUNX1 fusion.
Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Maharry, Kati , Becker, Heiko , Metzeler, Klaus H. , Whitman, Susan P., Eisfeld, Ann‐Kathrin , Schwind, Sebastian , Wu, Yue-Zhong, Kolitz, Jonathan E. , Baer, Maria R. , Powell, Bayard L., Bucci, Donna, Carroll, Andrew J. , Stone, Richard M. , Marcucci, Guido , Bloomfield, Clara D. , Papaioannou, Dimitrios , Mrózek, Krzysztof , Mendler, Jason H. , Nicolet, Deedra , Caligiuri, Michael A. , Volinia, Stefano

Mayo Clinic

Blood | October 14, 2019 | Volume: 122 | Issue: 21 | Pages: 2540-2540

10.1182/blood.v122.21.2540.2540 Get It

Abstract In CN-AML, mutations of specific genes have prognostic significance and are used for treatment guidance. However, these mutations are in general not mutually exclusive and CN-AML patients (pts) frequently harbor mutational combinations with unclear prognostic significance because of the concurrent presence of mutations with favorable (CEBPA, NPM1) and unfavorable (ASXL1, DNMT3A, IDH1, IDH2, FLT3-ITD, MLL-PTD, RUNX1, TET2, WT1) impact on outcome. Here, we report the frequency and clinical significance of isolated mutations and their combinations in 364 CN-AML pts. Younger [<60 years (y); n=163] and older (≥60 y; n=201) pts were intensively treated on frontline CALGB/Alliance protocols and, per protocol, did not undergo allogeneic stem cell transplantation in first complete remission (CR). Median follow-up for pts alive was 8.7 y. Pts were analyzed centrally for mutations in the ASXL1, CEBPA, DNMT3A, IDH1, IDH2, NPM1, RUNX1, TET2, and WT1 genes and the presence of FLT3-ITD, FLT3-TKD and MLL-PTD. We found that 99% of pts had ≥1 and 88% ≥2 of the 12 mutations. Specifically, 11% of pts had 1 gene mutated (n1), 40% had 2 (n2), 31% 3 (n3), and 18% harbored ≥4 mutated genes (n4). The distribution of the different n groups in younger and older pts was similar (Fig 1). The expected frequency of each mutated gene in every numerical (n) group was calculated as follows: [no. of pts with the mutated gene] x [total no. of mutations in the n group] / [total no. of mutations in all pts], and compared with the observed frequency. CEBPA, IDH2, NPM1, and RUNX1 mutations were overrepresented in the n1 and n2 groups (P<.001, P<.001, P=.002, P=.02, respectively) and thus likely represent “early” events in leukemogenesis. In contrast, DNMT3A, FLT3-ITD, and TET2 mutations were more frequent in the n3 and n4 groups (P=.008, P<.001, P=.02, respectively) suggesting that they are likely “late” events. The distribution among age groups and clinical impact of the “early” mutations (i.e., CEBPA, NPM1, IDH2) presenting as isolated mutations or in combination with other mutations were then investigated. Isolated RUNX1 mutations could not be evaluated due to small sample size. Younger pts were more likely to harbor an isolated “early” mutated gene than older pts (21% v 12%, P=.03). Specifically, isolated CEBPA and NPM1 mutations were more frequent in younger pts compared with the older (7% v 2%, P=.007; 7% v 3%, P=.07, respectively). In pts with isolated CEBPA mutations, these were always bi-allelic. Single “early” mutated genes varied in their impact on CR achievement (CEBPA: 100%, NPM1: 94%, IDH2: 67%), and overall survival (OS; 3-y OS: CEBPA: 87%, NPM1: 69%, IDH2: 22%). Acquisition of additional mutations adversely modified the prognostic significance of favorable “early” mutations in the CEBPA (Fig 2A) and NPM1 (Fig 2B) genes, but left unchanged the unfavorable effect of IDH2 mutations (Fig 2C). Two mutational combinations were exceptions to this: younger pts with both NPM1 and DNMT3A mutations (8 pts) had an excellent prognosis with 3-y OS of 100%; and older pts with concurrent NPM1 and IDH2 mutations (9 pts; all IDH2 mutations were in codon R140) had a high 3-y OS rate of 67%. We conclude that CEBPA and NPM1 mutations mainly define pts with favorable prognosis when they present as single markers, whereas mutated IDH2 predominantly associates with adverse outcome. The NPM1+DNMT3A and NPM1+IDH2 mutational patterns may define novel favorable molecular subtypes in younger and older CN-AML pts, respectively, but these results require corroboration in larger pt cohorts. Disclosures: Mrózek: AMERICAN SOCIETY OF HEMATOLOGY: I will review abstracls submitted for presentation at the 55th ASH Annual Meeting in the 611 category Other. Eisfeld:AMERICAN SOCIETY OF HEMATOLOGY: I will review abstracls submitted for presentation at the 55th ASH Annual Meeting in the 608 category Other.